Miyazaki M, et al. – This exploration was intended to examine the factors influenced the ability of tolvaptan (TLV) in liver cirrhosis. Between patients with liver failure and those with hepatocellular carcinoma (HCC) progression, development of ascites could differ. A sufficient preceding dose of furosemide decreased the diuretic effect of TLV.